Non-small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Epidermal Growth Factor Ointment for Patients With Erlotinib Related Skin Effects
Verified date | November 2014 |
Source | Dong-A University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
Epidermal growth factor receptor-tyrosin kinase inhibitor (EGFR-TKI, Erlotinib) has
demonstrated its efficacy in patients with non-small cell lung cancer and pancreatic cancer.
But, their use is associated with dermatologic reactions of varying severity. Incidence of
Erlotinib related skin effect (ERSE) was reported ~75% in NSCLC and pancreatic cancer phase
III trials. Even though the dermatologic reactions could be a surrogated marker, it may be
cause of dose modification. Also, it could give significant physical and psycho-social
discomfort to patients. However, there is still a wide variety of drugs used- including,
steroid, antibiotics, and vitamin D without any clear evidence based management
recommendation.
The role of epidermal growth factor (EGF) has been extensively investigated in normal and
pathological wound healing. It is implicated in keratinocyte migration, fibroblast function
and the formation of granulation tissue. The first growth factor to be isolated growth
factor therapy has progressed into clinical practice in the treatment of wounds.
Therefore, the investigators propose an epidermal growth factor ointment apply for patients
with Erlotinib related skin effects.
Status | Completed |
Enrollment | 52 |
Est. completion date | October 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Age :older than 20 - ECOG performance status 0 -2 - Histologically lung cancer or Pancreatic Cancer - Patients take Erlotinib following the reason Clinical failure of the prior therapy locally advanced or metastatic NSCLC The 1ST line using in combination with Gemcitabine for locally advanced, unresectable or metastatic Pancreatic Cancer(Adenocarcinoma) - Patients who have Erlotinib-treatment related skin lesions Gr=2 (NCI-CTC V3.0). - A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT), or 20 mm or longer in conventional CT (it should be used by a consistent method during the study period). - The following laboratory test results: Creatinine clearance = 60ml/min Number of absolute neutrophil counts (ANC) > 1.5 x 109/L Number of thrombocytes > 100 x 109/L Total bilirubin < 2x upper limit of normal ALAT, ASAT < 3 x upper limit of normal (in case of liver metastasis, 5 x upper limit of normal) Alkaline phosphatase < 3 x upper limit of normal (in case of liver metastasis, 5 x upper limit of normal) - A patient with the willingness to comply with the study protocol during the study period and capable of complying with it. - A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages. Exclusion Criteria: - A patient with previous active or passive immunotherapy. - A pregnant or lactating patient - A patient of childbearing potential without being tested for pregnancy at baseline for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.) - A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications. - A patient with history of dermatologic care (except transient urticaria) within 4 weeks - A patient with clinically significant (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or myocardial infarction within past 12 months. - A patient with interstitial pneumonia or diffused symptomatic fibrosis of the lungs. - Organ allogenic transplantation requiring immunosuppressive therapy. Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by case basis prior to enrolling the subject. - Known allergies, hypersensitivity, or intolerance to Study drugs, Chemotherapy drugs using this Clinical trial |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-A University Hospital | Busan |
Lead Sponsor | Collaborator |
---|---|
Dong-A University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of skin lesion grading by NCI-CTC v3.0 | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |